May 10, 2022
  • Pfizer Inc. said it will spend about $11.6 billion to buy the rest of Biohaven Pharmaceutical Holding Co., which makes the prescription migraine drug Nurtec. The deal, which is expected to be completed by early 2023, will give Pfizer full ownership of Biohaven after it acquired commercialization rights to Nurtec outside of the United States earlier this year. (Article here)